Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

As shown by table, males had significantly higher median (25th,75th) BUN, creatinine, uric acid, urine creatinine and urine phosphorous (15.8 (14.15,18.45) mg/dl, 1.1(1,1.25) mg/dl, 6.3 (5.65,7.25) mg/dl, 1538 (1150,1789.5) mg/24 h, 832 (663.75,1163.5) mg/24 h, respectively) than in females (14 (11.8,16.3) mg/dl, 0.8 (0.8,0.9) mg/dl, 4.4 (3.3,5.3) mg/dl, 1011 (725,1273.5) mg/24 h, 671 (484.5,814.5) mg/24 h, respectively) (p < 0.05).Comparison of clinical parameters and lab data between male and female in nephrolithiasis patientsClinical parametersTotalMale patientsFemale patientsp-valueMedian(25th: 75th)Median(25th: 75th)Median(25th: 75th)Age(years)47.5 ± 11.9450.19 ± 12.4345.04 ± 11.170.15BMI(Kg/m2)28.94 ± 4.2128.65 ± 4.9029.2 ± 3.560.67Lab data OPG(pmol/l)3.5(2.9 to 4)3.4(2.9 to 4.3)3.6(2.8 to 3.9)0.61 sRANKL(pmol/l)0.2(0.1 to 0.3)0.2(0.1 to 0.3)0.2(0.1 to 0.3)0.85 BUN(mg/dl)15.2(12.98 to 17.38)15.8(14.15 to 18.45)14(11.8 to 16.3)0.02 Creatinie (mg/dl)0.9(0.8 to 1.1)1.1(1 to 1.25)0.8(0.8 to 0.9)≤ 0.001 Uric acid (mg/dl)5.45(4.03 to 6.3)6.3(5.65 to 7.25)4.4(3.3 to 5.3)≤ 0.001 Ca(mg/dl)9.6(8.9 to 9.98)9.7(8.95 to 10.05)9.5(8.9 to 9.9)0.2 P(mg/dl)3.4(3.13 to 4.18)3.3(3 to 4)3.6(3.3 to 4.2)0.19 Urine volume(ml/24 h)1350(900 to 2237.5)1650(950 to 2237.5)1150(825 to 2250)0.39 Urine creatinine(mg/24 h)1227(949.5 to 1624)1538(1150 to 1789.5)1011(725 to 1273.5)0.003 Urine uric acid(mg/24 h)593(405 to 804.5)786(436 to 865.25)547(390 to 760.5)0.14 Urine calcium (mg/24 h)209.5(150 to 327)193.5(152.5 to 285)232(105 to 340.5)0.9 Urine phosphorus (mg/24 h)741.5(592.5 to 958)832(663.75 to 1163.5)671(484.5 to 814.5)0.04 PTH(pg/ml)32.9(24.65 to 42.83)36.1(27.1 to 41.8)31.1(20.7 to 61.4)0.5 Vitamin D(nmol/l)36.8(25.45 to 61.10)40(27.1 to 56.7)31.55(20.5 to 64.45)0.41 Urine citrate (mg/24 h)493(267 to 740)427(277 to 674)592(225 to 756.25)0.3 Na(mEq/l)137.4(136.8 to 138.35)137.3(136.75 to 138)137.5(136.8 to 139)0.5 eGFR (ml/minute)102.48(82.27 to 119.33)101.98(79.14 to 117.83)103.62(82.43 to 125.85)0.71 kidney stone disease duration (year)3.5(1, 11)3.25(1 to 8.88)4.5(1 to 11.5)0.66eGFR estimated glomerular filtration rate based on the Creatinine Cockcroft-Gault Equation

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were excluded if they had hyperparathyroidism, thyroid gland dysfunction, renal tubular acidosis, malignancy, longstanding corticosteroid intake.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis

Study design awaiting verification · BMC Nephrology · 2018

Original publication title

Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis

Asieh Mansour; Maryam Aboeerad; Mostafa Qorbani; Amir Pejman Hashemi Taheri; Mohamad Pajouhi; Abbas Ali Keshtkar; Bagher Larijani; Mohammad Reza Mohajeri-Tehrani; Mohammad Reza Ganji

© The Author(s). 2018

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.

Source: Background

Abstract: What methods does the paper describe?

Forty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.

Source: Methods

Abstract: Results

The median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = −.0344, P = 0.02).

Source: Results

Abstract: Conclusion

The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.

Source: Conclusion
Authors’ abstract

Background

Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.

Methods

Forty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.

Results

The median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = −.0344, P = 0.02).

Conclusion

The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.

Publication and source details

Original title: Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis

Asieh Mansour; Maryam Aboeerad; Mostafa Qorbani; Amir Pejman Hashemi Taheri; Mohamad Pajouhi; Abbas Ali Keshtkar; Bagher Larijani; Mohammad Reza Mohajeri-Tehrani; Mohammad Reza Ganji

BMC Nephrology · 2018

© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100004484Tehran University of Medical Sciences and Health Services26129Ganji Mohammad Reza

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:04:00.186877+00:00

DOI: 10.1186/s12882-018-0960-z · PMC6042206